Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 2/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.37 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276922 | 0.78 | KMT2A (0.51) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL267666 | 0.69 | ALDH1A1 (0.70) | MEN1KMT2ALMNAALDH1A1MAPT | |
| Bicarbonate SCHEMBL30096531 | 0.65 | ALDH1A1 (0.64) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL11296307 | 0.65 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL27583119 | 0.65 | CYP1A2 (0.51) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL27583120 | 0.64 | ALDH1A1 (0.65) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL13946243 | 0.63 | CYP1A2 (0.67) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL25337392 | 0.62 | MAPT (0.51) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL44366 | 0.62 | POLB (0.76) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL8094050 | 0.62 | POLB (0.76) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135221-B2 | Methods for inducing an immune response | MOONSHOT PHARMA LLC (US) | 2021-10-05 | — | — | US | claimed |
| WO-2005092304-A2 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2005-10-06 | — | — | WO | claimed |
| WO-2024255817-A1 | SYSTEMS AND METHOD OF INHIBITING NONSENSE-MEDIATED DECAY WITH CIRCULAR RNAS | PEKING UNIVERSITY (CN) | 2024-12-19 | — | — | WO | disclosed |
| US-11352624-B2 | Reducing nonsense-mediated MRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200283762-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3690048-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10647983-B2 | Reducing nonsense-mediated mRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2020-05-12 | — | — | US | disclosed |
| US-20170159049-A9 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2017-06-08 | — | — | US | disclosed |
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3041958-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160194630-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2016-07-07 | — | — | US | disclosed |
| WO-2015035091-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | MEN1 3033/4885KMT2A 1956/4885NPC1 2891/4885 |
| US-11135221-B2 | Methods for inducing an immune response | UPF1, RNGTT, NSUN2 | MEN1 3965/4885KMT2A 2543/4885NPC1 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.